These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32764625)

  • 1. ATIP3 deficiency facilitates intracellular accumulation of paclitaxel to reduce cancer cell migration and lymph node metastasis in breast cancer patients.
    Rodrigues-Ferreira S; Nehlig A; Kacem M; Nahmias C
    Sci Rep; 2020 Aug; 10(1):13217. PubMed ID: 32764625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.
    Rodrigues-Ferreira S; Nehlig A; Moindjie H; Monchecourt C; Seiler C; Marangoni E; Chateau-Joubert S; Dujaric ME; Servant N; Asselain B; de Cremoux P; Lacroix-Triki M; Arnedos M; Pierga JY; André F; Nahmias C
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23691-23697. PubMed ID: 31685623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics.
    Molina A; Velot L; Ghouinem L; Abdelkarim M; Bouchet BP; Luissint AC; Bouhlel I; Morel M; Sapharikas E; Di Tommaso A; Honoré S; Braguer D; Gruel N; Vincent-Salomon A; Delattre O; Sigal-Zafrani B; André F; Terris B; Akhmanova A; Di Benedetto M; Nahmias C; Rodrigues-Ferreira S
    Cancer Res; 2013 May; 73(9):2905-15. PubMed ID: 23396587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis.
    Rodrigues-Ferreira S; Di Tommaso A; Dimitrov A; Cazaubon S; Gruel N; Colasson H; Nicolas A; Chaverot N; Molinié V; Reyal F; Sigal-Zafrani B; Terris B; Delattre O; Radvanyi F; Perez F; Vincent-Salomon A; Nahmias C
    PLoS One; 2009 Oct; 4(10):e7239. PubMed ID: 19794912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microtubule-Associated Protein ATIP3, an Emerging Target for Personalized Medicine in Breast Cancer.
    Haykal MM; Rodrigues-Ferreira S; Nahmias C
    Cells; 2021 May; 10(5):. PubMed ID: 34062782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer.
    Zhang J; Zhang J; Xu S; Zhang X; Wang P; Wu H; Xia B; Zhang G; Lei B; Wan L; Zhang D; Pang D
    Cell Physiol Biochem; 2018; 45(2):692-705. PubMed ID: 29414807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative regulation of EB1 turnover at microtubule plus ends by interaction with microtubule-associated protein ATIP3.
    Velot L; Molina A; Rodrigues-Ferreira S; Nehlig A; Bouchet BP; Morel M; Leconte L; Serre L; Arnal I; Braguer D; Savina A; Honore S; Nahmias C
    Oncotarget; 2015 Dec; 6(41):43557-70. PubMed ID: 26498358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
    Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
    Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.
    Rodrigues-Ferreira S; Nehlig A; Monchecourt C; Nasr S; Fuhrmann L; Lacroix-Triki M; Garberis I; Scott V; Delaloge S; Pistilli B; Vielh P; Dubois T; Vincent-Salomon A; André F; Nahmias C
    Breast Cancer Res Treat; 2019 Feb; 173(3):573-583. PubMed ID: 30368744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Complete response of advanced breast cancer with lymph node metastases to nab-paclitaxel therapy-report of a case].
    Hara Y; Sakurai K; Enomoto K; Matsumoto K; Ueda Y; Hagiwara M; Waga E; Nagashima S; Tani M; Amano S
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2080-2. PubMed ID: 23267983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes for adjuvant treatment of early breast cancer.
    Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
    Wang H; Liu B; Zhang C; Peng G; Liu M; Li D; Gu F; Chen Q; Dong JT; Fu L; Zhou J
    J Pathol; 2009 May; 218(1):76-85. PubMed ID: 19214989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability.
    Luo Y; Li D; Ran J; Yan B; Chen J; Dong X; Liu Z; Liu R; Zhou J; Liu M
    Protein Cell; 2014 Jun; 5(6):469-79. PubMed ID: 24748116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.
    Ghaffari A; Hoskin V; Turashvili G; Varma S; Mewburn J; Mullins G; Greer PA; Kiefer F; Day AG; Madarnas Y; SenGupta S; Elliott BE
    Breast Cancer Res; 2019 Jan; 21(1):12. PubMed ID: 30678714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
    Vlastos G; Mirza NQ; Lenert JT; Hunt KK; Ames FC; Feig BW; Ross MI; Buzdar AU; Singletary SE
    Cancer; 2000 Mar; 88(6):1417-24. PubMed ID: 10717625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy.
    Shi X; Sun X
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):909-917. PubMed ID: 28741098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest.
    Zhao Y; Peng H; Liang L; Li Y; Hu X; Wang B; Xu Y; Chen S
    Breast Cancer Res Treat; 2022 Feb; 192(1):75-87. PubMed ID: 35079981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.
    Volk-Draper L; Hall K; Griggs C; Rajput S; Kohio P; DeNardo D; Ran S
    Cancer Res; 2014 Oct; 74(19):5421-34. PubMed ID: 25274031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
    Sun X; Li D; Yang Y; Ren Y; Li J; Wang Z; Dong B; Liu M; Zhou J
    J Pathol; 2012 Mar; 226(4):666-73. PubMed ID: 21989536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.